Comparison · NCT00537095-eeeeeb99
ZD6474 vs PLACEBO: Disease Control Rate at 6 Months
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ZD6474 vs PLACEBO: Disease Control Rate at 6 Months. Trial comparisons, record NCT00537095-eeeeeb99. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00537095-eeeeeb99
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.569 | 0.454 | 0.677 | wilson | |
| Risk in group 2 | 0.425 | 0.318 | 0.539 | wilson | |
| Risk difference, group 1 minus group 2 | 0.145 | -0.0174 | 0.297 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.34 | 0.96 | 1.87 | log | |
| Odds ratio, group 1 over group 2 | 1.79 | 0.928 | 3.46 | log | |
| Number needed to treat, for one more participant with the outcome on ZD6474 than on PLACEBO | 6.91 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ZD6474 | ZD6474, Vandetanib 300mg | 41 | 72 | OG000 |
| Group 2 | PLACEBO | PLACEBO | 31 | 73 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Disease Control Rate at 6 Months
- Description
number of participants that achieved disease control 6 months after randomization. Best objective response of complete response + partial response + stable disease \> 24 weeks according to RECIST criteria
- Time frame
- 6 months after randomization
- Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
- NCT number
- NCT00537095
- Phases
- PHASE2
- Conditions
- Thyroid Neoplasms
- Interventions
- Vandetanib, Placebo
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2011-07-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00537095?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00537095-eeeeeb99